Brief: 4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of Phase 3 Program
18/09/2024 21:48
Sept 18 (Reuters) - 4D Molecular Therapeutics Inc
FDMT.O :
* 4DMT HIGHLIGHTS ROBUST AND DURABLE CLINICAL ACTIVITY FOR
4D-150
AND DESIGN OF 4FRONT PHASE 3 PROGRAM AT 4D-150 WET AMD
DEVELOPMENT DAY
* 4D MOLECULAR THERAPEUTICS : EXPECT TO INITIATE 4FRONT-1 IN
Q1
2025
Source text for Eikon: ID:nGNX7V1f3P
Further company coverage: FDMT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on 4D Molecular Therapeutics
See all news4D Molecular Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
4D Molecular Therapeutics Q2 net loss widens
Brief: 4D Molecular Therapeutics Q2 Net Income USD -72.936 Million Vs. IBES Estimate USD -70.3 Million
4D Molecular Therapeutics Inc expected to post a loss of $1.02 a share - Earnings Preview
Brief: 4d Molecular Therapeutics Says 4D-150 Continues To Be Well Tolerated With No New Safety Findings